Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?

References

• Cazzola M, Rogliani P, Novelli L, et al. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013;14(18):2489–2499.
   PubMed Web of Science ®Google Scholar
• The Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2022. (cited 2021 Dec 28). Available at: https://goldcopd.org/.
   Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Lucas S, Lapperre T, et al. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. Respir Res. 2021;22(1):25. https://doi.org/10.1186/s12931-021-01615-0
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J. 2013;41(6):1252–1256.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Calle M, Molina J, et al. Spanish COPD guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):69–81.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis. Eur Respir J. 2020;56(suppl. 64):984.
   Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. https://doi.org/10.1016/S0140-6736(16)31354-X
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ritondo BL, de Marco P, et al. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2021;15(1):143–152.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126.
   PubMed Web of Science ®Google Scholar
• Yebyo HG, Braun J, Menges D, et al. Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit-harm modelling study. Lancet Digit Health. 2021;3(10):e644–e653.
   PubMedGoogle Scholar
• de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013;8(5):e62985.
   PubMedGoogle Scholar
• Roman-Rodriguez M, Kaplan A. GOLD 2021 strategy report: implications for asthma-COPD overlap. Int J Chron Obstruct Pulmon Dis. 2021;16:1709–1715.
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Hardin M, Christenson SA, et al. Clinical approach to the therapy of asthma-COPD overlap. Chest. 2019;155(1):168–177.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Rogliani P. Blood eosinophils in chronic obstructive pulmonary disease: is there enough evidence? Touchreviews Respir Pulm Dis. 2021;6(1):31–37.
   Google Scholar
• Harries TH, Rowland V, Corrigan CJ, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21(1):3.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Singh D, Jenkins C, et al. Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. Respir Res. 2020;21(1):17.
   PubMed Web of Science ®Google Scholar
• Liu T, Xiang ZJ, Hou XM, et al. Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:20406223211028768.
   Google Scholar
• Saito Z, Yoshida M, Kojima A, et al. Benefits and risks of inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease classified by blood eosinophil counts. Lung. 2020;198(6):925–931.
   PubMedGoogle Scholar
• Herland K, Akselsen J-P, Skjønsberg OH, et al. How representative are clinical study patients with asthma or COPD for a larger ‘real life’ population of patients with obstructive lung disease? Respir Med. 2005;99(1):11–19.
   PubMed Web of Science ®Google Scholar
• Savran O, Godtfredsen N, Sørensen T, et al. COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils? Respir Res. 2021;22(1):54.
   PubMedGoogle Scholar
• Yoon JK, Lee JK, Lee CH, et al. The association between eosinophil variability patterns and the efficacy of inhaled corticosteroids in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2020;15:2061–2070.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Barnes N, Bourke SC, et al. A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. Eur Respir J. 2021;58(3):2004522.
   PubMedGoogle Scholar
• Southworth T, Beech G, Foden P, et al. The reproducibility of COPD blood eosinophil counts. Eur Respir J. 2018;52(1):1800427.
   PubMedGoogle Scholar
• Long GH, Southworth T, Kolsum U, et al. The stability of blood eosinophils in chronic obstructive pulmonary disease. Respir Res. 2020;21(1):15.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Kusunose M, Sanda R, et al. Is blood eosinophil count a biomarker for chronic obstructive pulmonary disease in a real-world clinical setting? Predictive property and longitudinal stability in Japanese patients. Diagnostics (Basel). 2021;11(3):404.
   PubMedGoogle Scholar
• Mycroft K, Krenke R, Górska K. Eosinophils in COPD-current concepts and clinical implications. J Allergy Clin Immunol Pract. 2020;8(8):2565–2574.
   PubMed Web of Science ®Google Scholar
• Casanova C, Celli BR, de-Torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50(5):1701162.
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700.
   PubMed Web of Science ®Google Scholar
• Schumann DM, Tamm M, Kostikas K, et al. Stability of the blood eosinophilic phenotype in stable and exacerbated COPD. Chest. 2019;156(3):456–465.
   PubMed Web of Science ®Google Scholar
• Mathioudakis AG, Bikov A, Foden P, et al. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. Eur Respir J. 2020;55(5):1902119.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–725.
   PubMed Web of Science ®Google Scholar
• Huiart L, Ernst P, Ranouil X, et al. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J. 2005;25(4):634–639.
   PubMedGoogle Scholar
• Löfdahl CG, Postma DS, Pride NB, et al. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J. 2007;29(6):1115–1119.
   PubMed Web of Science ®Google Scholar
• Contoli M, Campo G, Pavasini R, et al. Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients. Eur J Intern Med. 2018;47:82–86.
   PubMed Web of Science ®Google Scholar
• Sin DD, Van Eeden SF, Man SF. Slaying the CVD dragon with steroids. Eur Respir J. 2010;36(3):466–468.
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Rinaldi B, et al. Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs. 2017;77(7):721–732.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. https://doi.org/10.1016/S0140-6736(16)30069-1
   PubMed Web of Science ®Google Scholar
• Shin J, Yoon HY, Lee YM, et al. Inhaled corticosteroids in COPD and the risk for coronary heart disease: a nationwide cohort study. Sci Rep. 2020;10(1):18973.
   PubMedGoogle Scholar
• Rodríguez LA, Wallander MA, Martín-Merino E, et al. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med. 2010;104(11):1691–1699.
   PubMedGoogle Scholar
• Lee YM, Kim SJ, Lee JH, et al. Inhaled corticosteroids in COPD and the risk of lung cancer. Int J Cancer. 2018;143(9):2311–2318.
   PubMed Web of Science ®Google Scholar
• Raymakers AJN, Sadatsafavi M, Sin DD, et al. Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. Eur Respir J. 2019;53(6):1801257.
   PubMedGoogle Scholar
• Ge F, Feng Y, Huo Z, et al. Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients: a comprehensive analysis of nine prospective cohorts. Transl Lung Cancer Res. 2021;10(3):1266–1276.
   PubMedGoogle Scholar
• Suissa S, Dell’Aniello S, Gonzalez AV, et al. Inhaled corticosteroid use and the incidence of lung cancer in COPD. Eur Respir J. 2020;55(2):1901720.
   PubMedGoogle Scholar
• Prekovic S, Schuurman K, Mayayo-Peralta I, et al. Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nat Commun. 2021;12(1):4360.
   PubMedGoogle Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Andersen JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. https://doi.org/10.1016/S0140-6736(16)30069-1
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929.
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52(6):1801230.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Fabbri L, Papi A, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. https://doi.org/10.1164/rccm.201911-2207OC
   PubMedGoogle Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. https://doi.org/10.1164/rccm.202006-2618OC
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ritondo BL, Matera MG, et al. Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. Expert Rev Respir Med. 2021. DOI:https://doi.org/10.1080/17476348.2021.1951237. Epub ahead of print
   Google Scholar
• Miravitlles M, Verhamme K, Calverley PMA, et al. A pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid. Int J Chron Obstruct Pulmon Dis. 2022;17:545–558. DOI:https://doi.org/10.2147/COPD.S350167
   PubMed Web of Science ®Google Scholar
• Keir HR, Contoli M, Chalmers JD. Inhaled corticosteroids and the lung microbiome in COPD. Biomedicines. 2021;9(10):1312. https://doi.org/10.3390/biomedicines9101312
   PubMed Web of Science ®Google Scholar
• Liu D, Zeng YY, Shi MM, et al. Glucocorticoids elevate Pseudomonas aeruginosa binding to airway epithelium by upregulating syndecan-1 expression. Front Microbiol. 2021;12:725483.
   PubMedGoogle Scholar
• Eklöf J, Ingebrigtsen TS, Sørensen R, et al. Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease. Thorax. 2021. DOI:https://doi.org/10.1136/thoraxjnl-2021-217160 Online ahead of print
   PubMed Web of Science ®Google Scholar
• Shafiek H, Verdú J, Iglesias A, et al. Inhaled corticosteroid dose is associated with Pseudomonas aeruginosa infection in severe COPD. BMJ Open Respir Res. 2021;8(1):e001067.
   PubMedGoogle Scholar
• Venkitakrishnan R, Ramachandran D, Augustine J, et al. Inhaled corticosteroids and risk of tuberculosis - How bad is the risk? Indian J Tuberc. 2022;69(2):128–130. Online ahead of print.
   PubMedGoogle Scholar
• Huang TM, Kuo KC, Wang YH, et al. Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids. BMC Infect Dis. 2020;20(1):706.
   PubMedGoogle Scholar
• Janson C, Stratelis G, Miller-Larsson A, et al. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3055–3064.
   PubMed Web of Science ®Google Scholar
• Choi J-H, Jeong K-B, Park YH, et al. Comparison of risk of pneumonia caused by fluticasone propionate versus budesonide in chronic obstructive pulmonary disease: a nationwide retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2021;16:3229–3237.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380.
   PubMed Web of Science ®Google Scholar
• Beech AS, Lea S, Kolsum U, et al. Bacteria and sputum inflammatory cell counts; a COPD cohort analysis. Respir Res. 2020;21(1):289.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Anzueto A, et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016;4(9):731–741.
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease. A network analysis. Am J Respir Crit Care Med. 2020;201(9):1078–1085.
   PubMed Web of Science ®Google Scholar
• Chen H, Feng Y, Wang K, et al. Association between inhaled corticosteroids and upper respiratory tract infection in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2020;20(1):282.
   PubMedGoogle Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 3;2014. DOI:https://doi.org/10.1002/14651858.CD010115.pub2 CD010115
   Google Scholar
• Chen H, Sun J, Huang Q, et al. Inhaled corticosteroids and the pneumonia risk in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:691621.
   PubMedGoogle Scholar
• Wise RA, Bafadhel M, Crim C, et al. Discordant diagnostic criteria for pneumonia in COPD trials: a review. Eur Respir Rev. 2021;30(162):210124.
   PubMedGoogle Scholar
• Bourbeau J, Bafadhel M, Barnes NC, et al. Benefit/risk profile of single-inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:499–517.
   PubMed Web of Science ®Google Scholar
• Ställberg B, Janson C, Lisspers K, et al. Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients. NPJ Prim Care Respir Med. 2020;30(1):47.
   PubMedGoogle Scholar
• Saeed MI, Eklöf J, Achir I, et al. Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease. Diabetes Obes Metab. 2020;22(8):1348–1356.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Targeting mechanisms linking COPD to type 2 diabetes mellitus. Trends Pharmacol Sci. 2017;38(10):940–951.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80(2):112–119.
   PubMed Web of Science ®Google Scholar
• Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019;30(6):1145–1156.
   PubMed Web of Science ®Google Scholar
• Chiu KL, Lee CC, Chen CY. Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan. Sci Rep. 2021;11(1):724.
   PubMed Web of Science ®Google Scholar
• Janson C, Lisspers K, Ställberg B, et al. Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the Arctic study. Eur Respir J. 2021;57(2):2000515.
   PubMedGoogle Scholar
• Liu SF, Kuo HC, Liu GH, et al. Inhaled corticosteroids can reduce osteoporosis in female patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1607–1614.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European respiratory society guideline. Eur Respir J. 2020;55(6):2000351.
   PubMed Web of Science ®Google Scholar
• Bloom CI, Douglas I, Usmani OS, et al. Inhaled corticosteroid treatment regimens and health outcomes in a UK COPD population study. Int J Chron Obstruct Pulmon Dis. 2020;15:701–710.
   PubMed Web of Science ®Google Scholar
• Jo T, Yasunaga H, Yamauchi Y, et al. Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study. ERJ Open Res. 2020;6(1):00246–2019.
   PubMedGoogle Scholar
• van den Bemt L, van den Nieuwenhof L, Rutjes A, et al. Pragmatic trial on inhaled corticosteroid withdrawal in patients with COPD in general practice. NPJ Prim Care Respir Med. 2020;30(1):43.
   PubMedGoogle Scholar
• Rogliani P, Ritondo BL, Gabriele M, et al. Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Rev Clin Pharmacol. 2020;13(9):977–990.
   PubMed Web of Science ®Google Scholar
• Griffith MF, Feemster LC, Zeliadt SB, et al. Overuse and misuse of inhaled corticosteroids among veterans with COPD: a cross-sectional study evaluating targets for de-implementation. J Gen Intern Med. 2020;35(3):679–686.
   PubMedGoogle Scholar
• Miravitlles M, Auladell-Rispau A, Monteagudo M, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021;30(160):210075.
   PubMedGoogle Scholar
• Savran O, Godtfredsen N, Sørensen T, et al. COPD patients prescribed inhaled corticosteroid in general practice: based on disease characteristics according to guidelines? Chron Respir Dis. 2019;16:1479973119867949.
   Google Scholar
• Larsson K, Ekberg-Jansson A, Stridsman C, et al. Adherence to treatment recommendations for chronic obstructive pulmonary disease - results from the Swedish national airway register. Int J Chron Obstruct Pulmon Dis. 2021;16:909–918.
   PubMed Web of Science ®Google Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904.
   PubMed Web of Science ®Google Scholar
• Maniscalco M, Martucci M, Fuschillo S, et al. A case scenario study on adherence to COPD GOLD recommendations by general practitioners in a rural area of southern Italy: the “progetto PADRE.” Respir Med. 2020;170:105985.
   PubMedGoogle Scholar
• Leung JM, Sin DD. Inhaled corticosteroids in COPD: the final verdict is. Eur Respir J. 2018;52(6):1801940.
   PubMedGoogle Scholar
• David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188–195.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Endo-phenotyping of COPD patients. Expert Rev Respir Med. 2021;15(1):27–37.
   PubMed Web of Science ®Google Scholar
• Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2):1900651.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234.
   PubMed Web of Science ®Google Scholar
• Scuri M, Singh D, Fabbri LM, et al. Single inhaler extrafine triple therapy improves clinical outcomes in GOLD B COPD patients: post-hoc analysis of the TRIBUTE study. Am J Respir Crit Care Med. 2018;197:A3041.
   Google Scholar
• Fabbri LM, Roversi S, Beghé B. Triple therapy for symptomatic patients with COPD. Lancet. 2017;389(10082):1864–1865.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Pini L. Inhaled corticosteroids in COPD: trying to make a long story short. Int J Chron Obstruct Pulmon Dis. 2020;15:821–829.
   PubMed Web of Science ®Google Scholar
• Fazleen A, Wilkinson T. Early COPD: current evidence for diagnosis and management. Ther Adv Respir Dis. 2020;14:1753466620942128. https://doi.org/10.1177/1753466620942128
   Web of Science ®Google Scholar
• Lu HH, Zeng HH, Chen Y. Early chronic obstructive pulmonary disease: a new perspective. Chronic Dis Transl Med. 2021;7(2):79–87.
   PubMedGoogle Scholar
• Soriano JB, Polverino F, Cosio BG. What is early COPD and why is it important? Eur Respir J. 2018;52(6):1801448. https://doi.org/10.1183/13993003.01448-2018
   PubMed Web of Science ®Google Scholar
• Cazzola M, Puxeddu E, Ora J, et al. Evolving concepts in chronic obstructive pulmonary disease blood-based biomarkers. Mol Diagn Ther. 2019;23(5):603–614. https://doi.org/10.1007/s40291-019-00413-1
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. The challenges of precision medicine in COPD. Mol Diagn Ther. 2017;21(4):345–355.
   PubMed Web of Science ®Google Scholar